CO6771428A2 - Composición efervescente en forma sólida para uso en aplicaciones vaginales para el tratamiento de infecciones vaginales - Google Patents

Composición efervescente en forma sólida para uso en aplicaciones vaginales para el tratamiento de infecciones vaginales

Info

Publication number
CO6771428A2
CO6771428A2 CO13187466A CO13187466A CO6771428A2 CO 6771428 A2 CO6771428 A2 CO 6771428A2 CO 13187466 A CO13187466 A CO 13187466A CO 13187466 A CO13187466 A CO 13187466A CO 6771428 A2 CO6771428 A2 CO 6771428A2
Authority
CO
Colombia
Prior art keywords
vaginal
treatment
solid form
effervescent composition
applications
Prior art date
Application number
CO13187466A
Other languages
English (en)
Inventor
Giovanni Mogna
Gian Paolo Strozzi
Luca Mogna
Original Assignee
Probiotical Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiotical Spa filed Critical Probiotical Spa
Publication of CO6771428A2 publication Critical patent/CO6771428A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con una composición efervescente en forma sólida para uso en aplicaciones vaginales para el tratamiento de infecciones vaginales.
CO13187466A 2011-01-28 2013-08-06 Composición efervescente en forma sólida para uso en aplicaciones vaginales para el tratamiento de infecciones vaginales CO6771428A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2011A000107A IT1403661B1 (it) 2011-01-28 2011-01-28 Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali.
IT000316A ITMI20110316A1 (it) 2011-01-28 2011-03-01 Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali.

Publications (1)

Publication Number Publication Date
CO6771428A2 true CO6771428A2 (es) 2013-10-15

Family

ID=43975441

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13187466A CO6771428A2 (es) 2011-01-28 2013-08-06 Composición efervescente en forma sólida para uso en aplicaciones vaginales para el tratamiento de infecciones vaginales

Country Status (22)

Country Link
US (2) US9492377B2 (es)
EP (1) EP2667849B1 (es)
JP (1) JP5992446B2 (es)
KR (1) KR101913797B1 (es)
CN (1) CN104519866A (es)
AU (1) AU2012210296B2 (es)
BR (1) BR112013018953B1 (es)
CL (1) CL2013002148A1 (es)
CO (1) CO6771428A2 (es)
DK (1) DK2667849T3 (es)
EC (1) ECSP13012844A (es)
ES (1) ES2751416T3 (es)
IT (2) IT1403661B1 (es)
MA (1) MA34926B1 (es)
MX (1) MX347165B (es)
PE (2) PE20140259A1 (es)
PL (1) PL2667849T3 (es)
PT (1) PT2667849T (es)
RU (1) RU2587717C2 (es)
TN (1) TN2013000310A1 (es)
UA (1) UA114888C2 (es)
WO (1) WO2012101500A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1403661B1 (it) 2011-01-28 2013-10-31 Probiotical Spa Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali.
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
ITRM20110477A1 (it) 2011-09-09 2013-03-10 Giovanni Mogna Composizione comprendente n-acetilcisteina e/o lisozima microincapsulato gastroprotetto in associazione con batteri probiotici in grado di ripristinare l'effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell
ITMI20111718A1 (it) 2011-09-23 2013-03-24 Probiotical Spa Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali.
ITMI20130793A1 (it) * 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti.
ITMI20130794A1 (it) * 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle vaginosi batteriche.
ITMI20130795A1 (it) * 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici e/o bifidobatteri per uso nel trattamento preventivo e/o curativo delle infezioni batteriche e/o delle infiammazioni del tratto urinario e/o della prostata che sono la causa di prostatiti e ipertrofia prostat
TWI643626B (zh) * 2013-08-12 2018-12-11 西班牙商巨妮亞實驗室有限公司 作為益生菌之乳桿菌屬菌株
JP6990922B2 (ja) 2015-05-11 2022-01-12 マイバイオティクス ファーマ リミテッド 腸における細菌のコロニー形成のために固体粒子上で生菌のバイオフィルムを成長させるためのシステムおよび方法
KR101980252B1 (ko) 2015-05-26 2019-05-21 (주)투라인스 질증 치료용 조성물
ITUB20153106A1 (it) * 2015-08-13 2017-02-13 Probiotical Spa Composizione di batteri lattici per uso nel trattamento delle infezioni causate da Propionibacterium acnes e in particolare per l'acne
MX2018002533A (es) * 2015-09-29 2018-06-27 Kimberly Clark Co Composicion sinergica para el mantenimiento de un equilibrio saludable de la microflora.
CN105534948B (zh) * 2015-12-17 2019-05-03 内蒙古双奇药业股份有限公司 一种可常温保存的阴道用活菌制剂及其制备方法
ITUB20159330A1 (it) * 2015-12-22 2017-06-22 Roelmi Hpc S R L Composizioni probiotiche e loro uso
BE1023643B1 (nl) * 2016-03-21 2017-06-01 Yun NV Vaginale preparaten voor het onderhouden en / of herstellen van een gezonde vrouwelijke microbiota
MA45334A (fr) * 2016-03-24 2019-01-30 Probiotical Spa Composition bactérienne d'acide lactique pour le traitement d'infections vaginales bactériennes par gardnerella vaginalis et, éventuellement, d'infections fongiques concurrentes
CA3018035A1 (en) * 2016-03-24 2017-09-28 Probiotical S.P.A. Lactic acid bacterial composition for the treatment of bacterial vaginal infections by gardnerella vaginalis and, if present, of concurrent fungal infections
WO2017184619A2 (en) * 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
RU2022101485A (ru) 2016-05-25 2022-04-27 Майбиотикс Фарма Лтд. Композиция и способы для микробиотной терапии
US11026883B2 (en) 2016-10-13 2021-06-08 Catalent U.K. Swindon Zydis Limited Lyophilized pharmaceutical compositions for vaginal delivery
CN106798755B (zh) * 2017-03-10 2020-09-15 山东神农医院管理有限公司 一种具有调理乳腺增生功能的益生菌组合物及其应用
CN106692204B (zh) * 2017-03-10 2020-05-22 泰安大凡神农生物有限公司 一种缓解或改善盆腔炎症的益生菌组合物及其制备方法
KR102014810B1 (ko) * 2017-09-04 2019-08-27 라임바이오파마 주식회사 질염 예방 및 치료용 조성물
TWI703991B (zh) * 2017-09-29 2020-09-11 榮華 曹 供給二氧化碳氣體的衛生用品
IT201800020425A1 (it) 2018-12-20 2020-06-20 Univ Degli Studi Di Modena E Reggio Emilia Lattobacilli con attività antimicrobica
CN109846846A (zh) * 2018-12-20 2019-06-07 赛奈金生物科技(上海)有限公司 一种含益生菌的泡腾缓释剂及其制备方法和应用
CN109740292A (zh) * 2019-01-30 2019-05-10 中国测绘科学研究院 一种基于多智能体的城市人口空间分布估算方法及装置
US11045507B2 (en) 2019-02-21 2021-06-29 Ewelina Sosnowska-Turek Bifidobacterium animalis AMT30 strain and the composition containing the strain of Bifidobacterium animalis AMT30
KR102063757B1 (ko) * 2019-05-03 2020-01-08 주식회사 메디오젠 가드네렐라 바기날리스 및 칸디다 알비칸스에 항균 효과를 갖는 질염 치료 또는 개선용 유산균
CN110547915A (zh) * 2019-08-29 2019-12-10 云南白药清逸堂实业有限公司 应用益生菌的卫生棉制品及其制备方法
CN111647525B (zh) * 2020-05-18 2022-08-05 深圳华大基因农业控股有限公司 复合益生菌、菌剂及其在制备防治白色念珠菌性阴道炎菌剂中的应用
KR102444746B1 (ko) * 2021-09-16 2022-09-19 일동바이오사이언스(주) 락토바실러스 카제이 idcc 3451을 포함하는 질염에 유용한 조성물
KR20230068336A (ko) * 2021-11-08 2023-05-17 주식회사 씨티씨바이오 질염 또는 요로감염증 유발 미생물에 항균활성을 지닌 유산균 및 그의 용도
CN114350576B (zh) * 2022-03-17 2022-06-07 烟台欣和企业食品有限公司 提高料酒抗风险能力的乳杆菌及其应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819838A (en) 1970-08-04 1974-06-25 Bush Boake Allen Ltd Encapsulated flavoring composition
JPS53121949A (en) 1977-03-31 1978-10-24 Yakult Honsha Kk Production of drink and food containing bifidobacterium cells
DE2757370A1 (de) 1977-12-22 1979-07-05 Bayer Ag Gasdichte kunststoff-aluminium-verbundfolien
CH637297A5 (fr) 1978-12-05 1983-07-29 Nestle Sa Microbille comprenant un microorganisme et son procede de fabrication.
JPS58152809A (ja) * 1982-03-05 1983-09-10 Eisai Co Ltd 安定な発泡性「膣」坐剤
US4670272A (en) 1985-11-08 1987-06-02 Frito-Lay, Inc. Thermostable creme
US5343672A (en) 1992-12-01 1994-09-06 Scherer Ltd R P Method for manufacturing freeze dried dosages in a multilaminate blister pack
CN1211188A (zh) * 1996-02-14 1999-03-17 普罗克特和甘保尔公司 用于泌尿生殖道和肠道疾病的组合物
EP0845350A1 (de) 1996-11-29 1998-06-03 Alusuisse Technology & Management AG Kalt-verformbare Verbundfolie
ATE314858T1 (de) 1998-04-01 2006-02-15 Ganeden Biotech Inc Erfahren zür verringerung von cholesterin mit bacillus coagulans sporen, systeme un zusammensetzungen
EP0956858B1 (en) * 1998-04-30 2001-10-31 Renata Maria Anna Cavaliere Vesely Pharmaceutical compositions containing Lactobacillus brevis and Lactobacillus salivarius for treatment of vaginal infections
RU2150268C1 (ru) 1998-12-25 2000-06-10 Быков Валерий Алексеевич Суппозиторий с лактобактериями для лечения дисбактериозов влагалища
IT1309427B1 (it) 1999-05-28 2002-01-23 Mendes S U R L Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso
CN1234373C (zh) * 2000-09-28 2006-01-04 信谊药厂 含嗜酸乳杆菌的药物制剂及制备方法
WO2004101770A1 (en) 2003-03-13 2004-11-25 Universite De Moncton (Bureau De Soutien A L'innovation) Antioxidant producing bacterium and uses thereof
US20040185032A1 (en) 2003-03-18 2004-09-23 David Burrell Compositions and methods for treating colic
AU2004228759B2 (en) * 2003-04-09 2010-04-08 Dolhay Klinika Egeszsegugyi Kft. Sexual hygienic composition
EP2033529B1 (en) 2003-10-24 2019-12-11 N.V. Nutricia Synbiotic composition for infants
DE50300325D1 (de) 2003-11-03 2005-03-31 Peter-Hansen Volkmann Vaginalpflegezusammensetzung
GB0330009D0 (en) * 2003-12-24 2004-01-28 Ferrosan As Probiotic tablet formulations
GB0405406D0 (en) 2004-03-10 2004-04-21 Edko Pazarlama Tanitim Ltd Sti Anti-vaginitis compositions
EP1600060A1 (en) 2004-05-25 2005-11-30 Cognis IP Management GmbH Oral and/or topical compositions comprising prebiotics and fatty acid
DE602004027120D1 (de) 2004-05-25 2010-06-24 Cognis Ip Man Gmbh Orale und/oder topische Zubereitungen
US8168171B2 (en) 2004-08-05 2012-05-01 Probiotical S.P.A. Folic acid producing bifidobacterium bacterial strains, formulations and use thereof
US20060039973A1 (en) * 2004-08-19 2006-02-23 Mary Aldritt Effervescent composition including water soluble dietary fiber
WO2006047680A2 (en) 2004-10-27 2006-05-04 North Carolina State University Lactobacillus acidophilus nucleic acids and uses thereof
KR100661032B1 (ko) 2005-04-19 2006-12-22 주식회사한국야쿠르트 간 기능 개선, 혈중 알코올 감소 및 항산화에 유효한조성물
WO2007100765A2 (en) 2006-02-28 2007-09-07 Childrens Memorial Hospital Lysozyme-modified probiotic components and uses thereof
RU2318523C2 (ru) 2006-03-13 2008-03-10 Лев Давидович Раснецов Средство антимикробного действия
EP2269465A1 (en) 2006-05-03 2011-01-05 Probiotical S.p.a. Compositions comprising Bifidobacterium adolescentis
ITMI20061841A1 (it) 2006-09-27 2008-03-28 Mofin S R L Colture liquide microbiche ad elevata stabilita' ed attivita' fermentativa
ITMI20062286A1 (it) * 2006-11-28 2008-05-29 Anidral Srl Una composizione per la somministrazione di principi biologicamente attivi in ambito ginecologico e rettale nonche' i suoi usi
US20080175899A1 (en) 2007-01-19 2008-07-24 Ross Mairi R Formulation for promoting sinus health in nasal cavities
US20080187628A1 (en) 2007-02-02 2008-08-07 Champion Melinda L Water-Soluble, Quick-Dissolve Flavor Tablets
PL210465B1 (pl) 2007-06-04 2012-01-31 Inst Biotechnologii Surowic I Szczepionek Biomed Społka Akcyjna Zastosowanie kompozycji szczepów z rodzaju Lactobacillus
WO2008153377A1 (en) 2007-06-15 2008-12-18 N.V. Nutricia Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide
DE102008023952A1 (de) 2008-05-16 2009-12-03 Alcan Technology & Management Ag Verpackungs-Deckfolie, Behältnis, Verpackung und Verpackungs-Produkt-Einheit
CN102124097B (zh) 2008-08-28 2013-11-06 科.汉森有限公司 细菌组合物
US9283252B2 (en) 2008-09-30 2016-03-15 Meiji Co., Ltd. Lactic acid bacterium having high oxalic acid decomposition ability
EP2403510B1 (en) 2009-03-05 2020-02-26 Probiotical S.p.A. Bacteria strains having a high anti-inflammatory activity
IT1400821B1 (it) 2009-03-09 2013-07-02 Probiotical Spa Sospensione oleosa contenente batteri probiotici per uso pediatrico
FI20095550A0 (fi) 2009-05-19 2009-05-19 Bayer Schering Pharma Oy Vaginaalinen antojärjestelmä
IT1397566B1 (it) 2009-05-27 2013-01-16 Probiotical Spa Lactobacillus pentosus produttore di batteriocine, composizioni alimentari e farmaceutiche contenenti lo stesso e relativo uso
JP5873018B2 (ja) 2009-07-27 2016-03-01 ネステク ソシエテ アノニム 繊維及びプロバイオティクスを含む栄養組成物
WO2011012932A1 (en) 2009-07-30 2011-02-03 Compagnie Gervais Danone Use of coated sterol or stanol particles for the preparation of food compositions having a low fat content and being essentially emulsifier-free
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
UA107711C2 (en) 2010-06-28 2015-02-10 Probiotical Spa Use of lactobacilli inhibiting gas producing coliform bacteria isolated from infants affected by colic
IT1403661B1 (it) 2011-01-28 2013-10-31 Probiotical Spa Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali.
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITRM20110477A1 (it) 2011-09-09 2013-03-10 Giovanni Mogna Composizione comprendente n-acetilcisteina e/o lisozima microincapsulato gastroprotetto in associazione con batteri probiotici in grado di ripristinare l'effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell
ITRM20110475A1 (it) 2011-09-09 2013-03-10 Probiotical Spa Ceppi di batteri lattici e/o bifido batteri, opzionalmente addizionati di n-acetilcisteina e/o lisozima microincapsulato gastroprotetto, aventi attivita' di inibizione/riduzione della crescita di differenti biotipi di e.coli, incluso e.coli o157:h7 e

Also Published As

Publication number Publication date
BR112013018953A2 (pt) 2017-07-11
MX2013008547A (es) 2013-12-02
ITMI20110107A1 (it) 2012-07-29
DK2667849T3 (da) 2019-10-28
RU2587717C2 (ru) 2016-06-20
ES2751416T3 (es) 2020-03-31
MA34926B1 (fr) 2014-02-01
IT1403661B1 (it) 2013-10-31
EP2667849A1 (en) 2013-12-04
NZ614002A (en) 2015-11-27
CN104519866A (zh) 2015-04-15
BR112013018953B1 (pt) 2020-12-29
ECSP13012844A (es) 2015-02-28
US9492377B2 (en) 2016-11-15
PT2667849T (pt) 2019-10-29
JP2014503581A (ja) 2014-02-13
PE20180413A1 (es) 2018-03-01
UA114888C2 (uk) 2017-08-28
KR20140029392A (ko) 2014-03-10
CL2013002148A1 (es) 2014-05-16
WO2012101500A1 (en) 2012-08-02
PE20140259A1 (es) 2014-03-08
AU2012210296A1 (en) 2013-08-22
RU2013137656A (ru) 2015-03-10
KR101913797B1 (ko) 2018-11-01
TN2013000310A1 (en) 2015-01-20
MX347165B (es) 2017-04-18
US20140065115A1 (en) 2014-03-06
AU2012210296B2 (en) 2017-01-05
ITMI20110316A1 (it) 2012-07-29
JP5992446B2 (ja) 2016-09-14
EP2667849B1 (en) 2019-07-24
US20170014335A1 (en) 2017-01-19
PL2667849T3 (pl) 2020-06-15

Similar Documents

Publication Publication Date Title
CO6771428A2 (es) Composición efervescente en forma sólida para uso en aplicaciones vaginales para el tratamiento de infecciones vaginales
CL2016001547A1 (es) Composiciones para el cuidado oral
SMT201500148B (it) Composizioni per uso nel trattamento di infezioni virali
GT201400033A (es) Pirimidinas anilladas sustituidas y uso de las mismas
CL2018000098A1 (es) Composiciones de plinabulina.
UY33754A (es) Monobactamas
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2015003019A1 (es) Derivados biaromáticos antibacterianos
EA201590270A1 (ru) Применение биотина для лечения рассеянного склероза
CL2014003059A1 (es) Uso de seaprose para eliminar biopelículas bacterianas; composicion de seaprose.
UY34008A (es) ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.
CO6741223A2 (es) Derivados de azetidina útiles para el tratamiento de enfermedades metabólicas e inflamatorias
CL2015001562A1 (es) Método para obtener una vacuna de mycoplasma.
BR112014030720A8 (pt) composto, composição farmacêutica e usos de inibidores de fbx03
CL2012001757A1 (es) Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica; y su uso en el tratamiento de infecciones micoticas.
CL2013000335A1 (es) Forma altamente cristalina de valsartan; proceso para prepararla; composicion farmaceutica que la comprende y uso en el tratamiento de la hipertension.
CR20160227A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
UY34154A (es) Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel.
ECSP16024805A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
ECSP16024798A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
EA201492280A1 (ru) Стабильный состав пексиганана
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma
PA8846601A1 (es) Tratamiento de infecciones bacterianas intracelulares
CO6801770A2 (es) Uso de secnidazol en el tratamiento de infecciones dentales
PE20151432A1 (es) Formulaciones de lorazepam de liberacion sostenida